Roaccutane in medicines safety update

The TGA has issued a reminder to health professionals about the potential risks of psychiatric adverse risks associated with isotretinoin (Roaccutane) and the need for careful psychological assessment before and during the treatment.The warning is based on a TGA evaluation of the findings of a UK Medicines and Healthcare Products Regulatory Agency report about the

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous St Vincent's report highlights hospital pharmacist role
Next Go rural, urges Ekka's Miss Popular